item management s discussion and analysis of financial condition and results of operations results of operations fiscal compared to fiscal total revenues for the year ended december  decreased by  to  from  in product sales for the year ended december  decreased by  to  from  in  primarily due to a decrease in the sales of first defense r and the termination of the license to market the kamar heatmount detector 
product selling prices have generally been held without increase in consideration of the difficult economic times being experienced by the company s core end users  dairy producers 
grant income increased by  to  in royalty income decreased by  to  in in  revenue from the sale of technology rights included  earned upon the termination of a license covering certain of the diffgam technology rights   earned under this license before it was cancelled   from an option to the lactoferrin technology and  from a different license to the diffgam technology 
in  revenue from the sale of technology rights included  earned from a license to the diffgam technology and  earned from an option to the lactoferrin technology 
grant income increased to  of total revenues in as compared to  of total revenues in most of the grant income supported work on the development of mast out tm and new approaches to the diagnosis of johne s disease 
sales of first defense decreased by during the year ended december  in comparison to the same period in sales have benefited from the withdrawal of a competitive product from the market and from a significant increase in the value of calves 
however  this positive affect was more than offset by negative pressures relating to a decline in milk prices and a backlog of orders 
milk prices are currently at levels last experienced in the s  resulting in difficult economic pressures for dairy producers 
sales of first defense have been negatively affected by this significant decline in milk prices 
the sales of first defense are normally seasonal with highest sales expected in the winter months 
a sudden increase in sales volume resulted in an unexpected reduction in product inventory levels creating a backlog of orders worth approximately  as of march  the backlog of orders was filled as of june   and then the backlog of orders increased to approximately  as of december  and to  as of september  the company completed a facility addition in may to increase its production capacity and eliminated the backlog of orders as of december  distributor order patterns may have been influenced by the backlog of orders in sales of wipe out r dairy wipes increased by during the twelve month period ended december  in comparison to the same period in sales of wipe out were first recorded in following the december acquisition of the product 
on october   the company agreed to accept  from kamar  inc of steamboat springs  colorado in consideration of the early termination of the license to market the kamar heatmount detector 
since  the company had marketed kamar s product that is used to detect standing heat in cows  under an exclusive license that was set to expire on december  the  approximates the net present value of the expected net contribution from the product over the final twenty seven months of the license term  had it not been terminated 
as this license had no book value  the full amount of the proceeds was recorded as a pre tax gain of  the  was recorded as other income in the fourth quarter of as a result of the termination of this license  the company s product sales  product costs and sales and marketing expenses were reduced beginning october  the following unaudited  pro forma  condensed financial information gives effect to this transaction as if it had occurred as of the beginning of the twelve month periods ended december  and year ended pro forma year ended pro forma december  adjustments adjusted december  adjustments adjusted product sales       product costs       sales and marketing expenses       net operating income       net interest and other income      income before taxes       tax expense       net income       diluted net income per common share product costs amounted to of product sales in as compared to in internally developed products tend to have higher gross margin percentages than licensed in products 
a moderately lower gross margin percentage is anticipated as new products initially are developed and acquired 
over time  as these products are fully integrated into the company s manufacturing and marketing operations  the company expects to be able to improve the gross margin percentage 
this is the case  for example  with wipe out dairy wipes  a product that was acquired by the company in december in  the company invested in the necessary facility addition and production equipment required to process the wipe stock and perform the filling operations for this product internally  which has caused an improvement in the gross margin 
at this stage in the company s development  management is focusing on growing the absolute dollar value of the gross margin from the products that the company continues to sell 
the company increased its expenditures for research and development by approximately  to  in as compared to  in research and development expenses aggregated and of total revenues in and  respectively 
research and development expenses exceeded grant income by approximately  in and by  in these net research and development expenses increased to of product sales in from of product sales in since  the company has shifted the primary focus of its research and development efforts to products for the animal health industry 
the majority of the company s research and development budget is focused on the development of a product utilizing nisin as an intramammary infusion intended to treat bovine mastitis 
to expand its commercialized line of products for use by dairy and beef producers  the company has also invested in the development of new diagnostic products leveraging the company s experience with infectious diseases 
sales and marketing expenses decreased by approximately  to  in  aggregating of product sales in  compared to in the company anticipated the decrease in the aggregate dollar amount of these expenses following the october  termination of the license to market the kamar heatmount detector  a product that had comprised a significant percentage of total sales 
the company continues to leverage the efforts of its small sales force through veterinary distribution channels 
general and administrative expenses decreased by approximately  to  in as compared to  in the company continues its efforts to control its general and administrative expenses while incurring all the necessary expenses associated with being a publicly held company 
interest income exceeded interest expense by approximately  and  in and  respectively 
interest expense was incurred in both years on the company s outstanding bank debt before it was repaid in may other income in included a one time payment of  accepted by the company in consideration of the october  termination of the license to market the kamar heatmount detector 
the income before taxes of  for the year ended december  compares to  for the year ended december  in and  the company recorded tax expense at an effective tax rate of and  respectively  resulting in net income of  and  for the years ended december  and  respectively 
the company utilized deferred tax benefits associated with certain net operating loss carryforwards of  and  as of december  and  respectively  that would offset future tax liabilities 
fiscal compared to fiscal total revenues for the year ended december  increased by  to  from  in product sales for the year ended december  increased by  to  from  in product selling prices have generally increased in line with inflation 
grant income increased by  to  in royalty income increased by  to  in revenue from the sale of technology rights was first recorded in aggregate sales of the two leading revenue generating products  first defense r and the kamar r heatmount r detector  totaled approximately  of total product sales for the year ended december  as compared to approximately  of total product sales for the year ended december  aggregate sales of the three leading revenue generating products  first defense  the kamar heatmount detector and wipe out r dairy wipes totaled approximately  of total product sales for the year ended december  as compared to approximately  of total product sales for the year ended december  in  for the first time  annual sales of first defense exceeded annual sales of the kamar heatmount detector 
sales of first defense have benefited from the withdrawal of a competitive product from the market and from a significant increase in the value of calves 
the sales of first defense are seasonal with highest sales expected in the winter months 
a sudden increase in sales volume resulted in an unexpected reduction in product inventory levels creating a backlog of orders worth approximately  as of march  the backlog of orders was filled as of june  and then increased to approximately  as of december  there was no backlog of orders as of december  effective october   the company accepted  in consideration of the early termination of the license covering sales of the kamar heatmount detector 
sales of wipe out were first recorded in following the december acquisition of the product 
grant income increased to approximately  of total revenues in as compared to  of total revenues in most of the grant income in supported work on the development of mast out tm and new approaches to the diagnosis of johne s disease 
in october  the company was awarded approximately  under a federal research grant to partially fund the company s efforts to develop a product to prevent travelers diarrhea 
in  the remaining funding then available under this grant was reallocated to the development of diffgam 
approximately  in grant income was recognized under this grant in product costs amounted to of product sales in as compared to in internally developed products tend to have higher gross margin percentages than licensed in products 
some deterioration of the gross margin percentage is anticipated as new products initially are developed and acquired 
over time  as these products are fully integrated into the company s manufacturing and marketing operations  the company expects to be able to improve the gross margin percentage 
this is the case  for example  with wipe out dairy wipes  a product that was acquired by the company in december in  the company invested in the necessary facility addition and production equipment to eliminate the need for a subcontractor and be able to manufacture this product internally  which  the company believes  should improve the gross margin 
at this stage in the company s development  management is focusing on growing the absolute dollar value of the gross margin on product sales 
the gross margin on product sales earned in increased by  to  as compared to the gross margin earned in the company decreased its expenditures for research and development by approximately  to  in as compared to  in research and development expenses aggregated and of total revenues in and  respectively 
research and development expenses exceeded grant and technology licensing income by approximately  in and by  in these net research and development expenses decreased to of product sales in from of product sales in since  the company has shifted the primary focus of its research and development efforts to products for the animal health industry 
to expand its commercialized line of products for use by dairy and beef producers  the company has invested in the development of new diagnostic products leveraging the company s experience with infectious diseases 
the company has also initiated development programs for certain disease preventive products 
before funding of diffgam development was stopped in  the company demonstrated preliminary efficacy in a phase i ii clinical trial to prevent and treat clostridium difficile associated diarrhea 
for clinical development to proceed into more expensive phase ii and iii trials  a partner would be required 
sales and marketing expenses increased by approximately  to  in  aggregating of product sales in  compared to in the company anticipated the modest increase in the ratio of these expenses to product sales as the company initiated sales of new products in the company continues to leverage its small sales force through veterinary distribution channels 
general and administrative expenses increased by approximately  to  in as compared to  in while the company continues its efforts to control its general and administrative expenses while incurring all the necessary expenses associated with being a publicly held company  the increase is in proportion to the growth of the company 
interest and other income exceeded interest expense by approximately  and  in and  respectively 
interest expense was incurred in both years on the company s outstanding bank debt 
the income before taxes of  for the year ended december  compares to  for the year ended december  in  the company recorded tax expense at a relatively typical corporate effective tax rate resulting in net income of  for the year ended december  during  the taxable income was fully offset by available net operating loss carryforwards resulting in no tax expense being recorded 
given the two consecutive years of profitable results in and and the expectation of continued profitability  the company recorded approximately  in non cash tax benefits in relating to the partial release of valuation allowances previously established against deferred tax benefits associated with certain net operating loss carryforwards that would offset future tax liabilities  in accordance with financial accounting standards board statement no 
as a result of this accounting for income taxes  the company recorded net income of  for the year ended december  financial position  liquidity and capital resources the company s total assets increased  or by  to  at december  from  at december  the company s cash and short term investment balance as of december  increased  or by  to  from  at december  net working capital increased  or by  to  at december  from  at december  stockholders equity increased  or by  to  at december  from  at december  during  approximately  in cash was provided by operating activities 
a significant portion of this cash was generated from two non recurring transactions  the  license termination payment and the  sale of technology rights  discussed above 
the net income of  was net of  in non cash depreciation and amortization expense  and tax expense includes approximately  of non cash items relating to deferred taxes 
as of december   the company had  in deferred tax assets available to reduce future tax liabilities 
the accounts receivable balance was reduced by approximately  due  in large part  to the termination of a license to a product effective october   and deferred revenue increased by  the inventory balance increased by  and accounts payable and accrued expenses were reduced by  the company anticipates being able to maintain positive cash flow from operating activities during the next twelve months 
investing activities were comprised of a  net investment in fixed assets and a net investment of  in short term investments 
financing activities included payments of  in debt principal that fully repaid all of the company s previously outstanding bank debt and approximately  in proceeds from the issuance of common stock upon the exercise of stock options 
the company funded its research and development expenses from product sales  grant income  and revenue from the sale of technology rights 
the company s fourth consecutive year of profitability has provided positive cash flow to fund all operating expenses as well as new product acquisitions while reporting a net operating income 
during the year ended december   the  gross margin from product sales almost funded the aggregate of  in research and development expenses net of grant income net r d and selling  general and administrative s  g a expenses 
in  the  gross margin more than funded the aggregate of  in net r d and s  g a expenses 
in  the  gross margin more than funded the aggregate of  in net r d and s  g a expenses 
in  the  gross margin more than funded the aggregate of  net r d and s  g a expenses 
since  it has been the company s strategy to focus its research and development efforts on animal health product opportunities  which are generally less expensive than human health product opportunities 
in march  the company received a two year grant award aggregating up to  from the maine technology institute  a non profit corporation created by the general assembly of the state of maine 
the grant augments the company s development of its nisin based mastitis treatment  mast out tm  by funding significant portions of the costs related to conducting the clinical trials and developing the proprietary manufacturing process required to obtain fda approval of the product 
the grant award carries a contingent payback obligation of  at the company s option  either the amount of the paid award within two years of first commercial sale of a product developed with the funding or a royalty on any sales of a product developed with the funding until the royalty aggregates two times the amount of the paid award 
because of this contingent payback obligation  the funding is being recorded as deferred revenue as the cash is received by the company  and no income is being recognized to match the development expenses as they are incurred 
there is no payback obligation in the event that a product is not commercialized 
in such case  the deferred revenue would be recognized at the time the product development effort is discontinued 
the company received  under this grant in and another  in and expects to receive the final  in since  the company has been awarded seven phase i and three phase ii small business innovation research sbir grants from the national institutes of health 
in addition  the company has been awarded two phase i sbir grants from the usda and three grants from the state of maine and one grant from the american water works association research foundation 
these grants aggregate approximately  in funding for the company s research and development programs 
approximately  of this grant funding was awarded by the national institutes of health and  by the state of maine and  by the usda 
in addition to the  that supported the development of the company s milk antibody products for humans  approximately  has been awarded in support of the mast out development program   has been awarded in support of skin sanitizing applications of nisin   was awarded in support of crypto scan r and  has been awarded in support of new approaches to the diagnosis of johne s disease 
approximately  of this grant income was recognized prior to  approximately  was recognized in and approximately  is expected to be recognized in not including the  award from the maine technology institute  described above 
the company may  on occasion  seek additional research grant support as a means of leveraging the funds that it is able to spend developing new products 
in may  the company utilized approximately  in available cash to repay the outstanding balance of its bank debt obligations 
as a result  there was no outstanding bank debt as of december  in comparison to  as of december  forward looking statements the statements contained in this report which are not historical fact are forward looking statements that involve various important assumptions  risks  uncertainties and other factors 
such forward looking statements include  but are not limited to  projections about future financial results  estimates of potential market sizes and product sales  and the timing of product development efforts 
there can be no assurance that actual results will not differ materially from those projected or suggested in such forward looking statements as a result of various factors including  but not limited to  the risk factors discussed below 
the company is heavily dependent on the successful development of new products for its future growth 
these new products have the potential to increase the company s profitability 
it is the company s objective to fund all selling  general and administrative expenses as well as all research and development expenditures that are not funded by grant income with the gross margin earned from product sales and with other income 
continuation of the company s profitability in the near term will  in large part  be determined by the ongoing successful marketing of first defense r 
growth in the company s profitability will  in large part  be determined by the success of the company s efforts to effectively develop  acquire and market new animal health products 
to advance the development of mast out toward fda licensure  the company would be required to incur significant outside laboratory expenses to fund the required toxicology  safety and efficacy trials 
the company paid approximately  towards these expenses in the fourth quarter of and anticipates that these expenses could aggregate approximately an additional  in it is the company s intention to initiate a pivotal clinical trial of this product during the summer of depending on the enrollment rate of cows  completion of this trial is expected in the fourth quarter of or first quarter of subject to the pace and success of the regulatory process  it is the company s objective to begin marketing this product in given the potential sales of this product that could be achieved if it is successfully developed and approved by the fda with the product claims being pursued by the company  management believes the significant investment is warranted 
the company estimates that the north american market for products in this category in lactating cows is approximately  per year and that an additional  but smaller  market opportunity exists for a potential dry cow application of the product  which would be subject to a separate new animal drug application and product license approval 
the company estimates that north american sales of what could be the first non antibiotic treatment for mastitis in lactating cows without a milk discard requirement could approximate  per year 
management believes that an additional  but smaller  sales potential exists for the potential dry cow application of the product and for both product indications in markets outside of north america 
given the  in other income from the sale of a joint venture that is to be recorded in the first quarter of together with normal business operations  the company expects a profitable first quarter of the significant outside laboratory expenses  discussed above  may result in net losses for any of the last three quarters of the year  while the company expects to be able to maintain its annual profitability for a fifth consecutive year 
given the receipt of the  described above  together with normal business operations  the company expects to have in excess of  in available cash and short term investments as of march  the company is considering its investment options for this cash that include  but are not limited to  the following i funding product development  ii investing in the manufacturing of its commercialized products  iii acquiring new products and iv repurchasing a limited amount of its outstanding common stock 
risk factors the development of these new products is subject to financial  efficacy  regulatory and market risks 
there can be no assurance that the company will be able to finance the development of these new product opportunities nor that  if financed  the new products will be found to be efficacious and gain the appropriate regulatory approval 
furthermore  if regulatory approval is obtained  there can be no assurance that the market estimates will prove to be accurate or that market acceptance at a profitable price level can be achieved or that the products can be profitably manufactured 
the company believes that supplies and raw materials for the production of its products are readily available from more than one vendor or farm 
it is the company s policy to maintain more than one source of supply for the components used in the company s products 
however  there is a risk that the company could have difficulty in efficiently acquiring essential supplies 
first defense r is sold in the united states subject to a product license approval from the usda first obtained in the potency of serial lots is directly traceable to the original serial used to obtain the product performance claims the reference standard 
due to the unique nature of the first defense label claims  host animal re testing is not required as long as periodic laboratory analyses continue to support the stability of stored reference standard 
to date  these analyses have demonstrated strong stability 
however  if  at any time  the usda does not approve the requalification of the reference standard  additional clinical studies could be required to meet regulatory requirements and allow for continued sales of the product 
the dairy industry is facing very difficult economic pressures at present 
many small farmers are being forced out of business 
milk prices are currently at levels last experienced in the s 
the financial insecurity of the company s primary customer base is a risk to the company s ability to maintain and grow sales at a profitable level 
additionally  the potential for epidemics of bovine diseases such as foot and mouth disease  bovine tuberculosis  brucellosis and bovine spongiform encephalopathy present a risk to the company and its customers 
the threat of biological terrorism is a risk to both the company s ability to economically acquire and collect good quality raw material from the company s contract farms as well as to the economical health of its customers 
any act of widespread bioterrorism against the dairy industry could have a negative impact on the company s operations 
effects of inflation and interest rates the company believes that neither inflation nor interest rates have had a significant effect on revenues and expenses 
new accounting pronouncements in april  the financial accounting standards board fasb issued statement of financial accounting standards sfas no 
 rescission of fasb nos 
 and  amendment of fasb statement no 
 and technical corrections sfas no 

sfas no 
rescinds fasb sfas no 
 reporting gains and losses from extinguishment of debt  and an amendment of sfas no 
 extinguishments of debt made to satisfy sinking fund requirements 
sfas no 
also rescinds sfas no 
 accounting for intangible assets of motor carriers  sfas no 
amends sfas no 
 accounting for leases  to eliminate an inconsistency between the required accounting for sale leaseback transactions and the required accounting for certain lease modifications that have economic effects that are similar to sale leaseback transactions 
sfas no 
also amends other existing authoritative pronouncements to make various technical corrections  clarify meanings  or describe their applicability under changed conditions 
adoption of certain provisions of sfas no 
was required after may   while other provisions must be adopted with financial statements issued after may  or the year beginning after may  the company does not expect adoption of sfas no 
to have a material impact on its operations 
in june  the fasb issued sfas no 
 accounting for costs associated with exit or disposal activities sfas no 

this statement addresses financial accounting and reporting for costs associated with exit or disposal activities and nullifies emerging issues task force eitf issue no 
 liability recognition for certain employee termination benefits and other costs to exit an activity including certain costs incurred in a restructuring 
adoption of sfas no 
is required for exit or disposal activities initiated after december  the company does not expect adoption of sfas no 
to have material impact on its operations 
in december  the fasb issued sfas no 
 accounting for stock based compensation sfas no 

this statement provides alternative methods of transition for a voluntary change to the fair value based method of accounting for stock based employee compensation 
additionally  sfas no 
amends the disclosure requirements of statement to require prominent disclosures in both annual and interim financial statements about the method of accounting for stock based employee compensation and the effect of the method used on reported results 
the company adopted the additional disclosure provisions of this statement required for the year ended december  and will include the prescribed additional disclosures in the company s future filings on form q 
in november  the fasb s emerging issues task force reached consensus on eitf no 
 accounting for revenue arrangements with multiple deliverables eitf no 

eitf no 
addresses the accounting treatment for arrangements that provide for the delivery or performance of multiple products or services where the delivery of a product  system or performance of services may occur at different points in time or over different periods of time 
eitf no 
requires the separation of the multiple deliverables that meet certain requirements into individual units of accounting that are accounted for separately under the appropriate authoritative accounting literature 
eitf no 
is applicable to revenue arrangements entered into in fiscal periods beginning after june  the company does not expect the provisions of eitf no 
to have a material impact on its results of operations or financial position 
critical accounting policies the consolidated financial statements are presented on the basis of accounting principles that are generally accepted in the us all professional accounting standards that are effective as of december  have been taken into consideration in preparing the consolidated financial statements 
the preparation of consolidated financial statements requires that the company make estimates and judgments that affect the reported amounts of assets  liabilities  revenues and expenses  and related disclosure of contingent assets and liabilities 
on an on going basis  the company evaluates its estimates  including those related to revenue recognition  investments  intangible and long lived assets  income taxes and contingencies 
the company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances  the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources 
actual results may differ from these estimates under different assumptions or conditions 
the company has chosen to highlight certain policies that it considers critical to the operations of the business and understanding its consolidated financial statements 
revenues related to the sale of manufactured products are recorded when title and risk of loss has passed to the customer  which is at the time of shipment and when collectibility is reasonably assured 
non refundable grant income is recognized as reimbursable expenses are incurred 
indirect costs which are billed to the government are subject to their review 
all research and development costs are expensed as incurred  as are all related patent costs 
royalty income is recorded on the accrual basis based on sales as reported to the company by its licensee pursuant to the terms of the agreement 
the company recognizes revenue in accordance with staff accounting bulletin sab no 
 revenue recognition in financial statements sab no 

sab no 
requires that four criteria are met before revenue is recognized 
these include i persuasive evidence that an arrangement exists  ii delivery has occurred or services have been rendered  iii the seller s price is fixed and determinable and iv collectibility is reasonably assured 
the company recognizes revenue at the time of shipment including to distributors for substantially all products  as title and risk of loss pass to the customer on delivery to the common carrier 
the company recognizes service revenue at the time the service is performed 
the company records estimated reductions to revenue in connection with customer programs and incentive offerings  which may give customers future rights such as free or discounted goods or services or trade in rights 
the company estimates these reductions based on its experience with similar customer programs in prior years 
the company s distributors of first defense r have the right to return expired product for a credit on future orders 
as the product has a two year shelf life  the company has not experienced significant product returns historically 
inventories include raw materials  work in process and finished goods and are recorded at the lower of standard cost which approximates cost on the first in  first out method or market net realizable value 
work in process and finished goods inventories include materials  labor and manufacturing overhead 
the company utilized approximately  and  of net operating loss carryforwards to offset taxable income in fiscal years and  respectively 
as a result of the company s two consecutive years of profitable results in and and the expectation of continued profitability  the company recorded a tax benefit of approximately  in fiscal as a result of the release of the valuation allowance on the deferred tax asset related to net operating loss carryforwards 
the remaining valuation allowance related to the general business credit carryforward of approximately  and  as of december  and  respectively  has not been released due to the uncertainty of its use before expiration 
this credit expires in the years through for federal and state income tax purposes  the company has remaining net operating loss carryforwards of approximately  expiring from to  that are available to offset future taxable income 
accounts receivable are recorded net of a valuation allowance for doubtful accounts of approximately  and  at december  and  respectively 
item a quantitative and qualitative disclosures about market risk none 
